Answers are grounded in this paper and cite their sources.
Open label extension studies allow continued prescribing of unlicensed drugs after a randomised trial, but it is unclear whether patients or drug companies are benefiting the most
No takes yet. Share an insight, caveat, or question.
Taylor et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: